Litigation Details for Pfizer Inc. v. Changzhou Pharmaceutical Factory (D. Del. 2024)

Pfizer Inc. v. Changzhou Pharmaceutical Factory (D. Del. 2024)

Docket		Date Filed	2024-05-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	11,083,724; 8,314,117; 8,759,372
Attorneys	Megan Elizabeth Dellinger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Pfizer Inc. v. Changzhou Pharmaceutical Factory (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-05-23				External link to document

Pfizer Inc. v. Changzhou Pharmaceutical Factory (1:24-cv-00623) Litigation Summary and Patent-Strategy Analysis

Last updated: July 27, 2026

Executive summary

• Case: Pfizer Inc. v. Changzhou Pharmaceutical Factory, 1:24-cv-00623 (U.S. District Court).
• Timing: Filed in 2024. The case is not a full “Paragraph IV” action summary without the FDA product/Orange Book and the asserted patents, which are required to map exclusivity and validity risk.
• Litigation use-case for pharma: This docket pattern typically signals a patent-infringement dispute tied to an FDA submission (often an ANDA) and Pfizer’s listed IP for the relevant drug substance or formulation.
• Actionable gap: A litigation summary and analysis that is accurate on (i) asserted patents, (ii) claim construction, (iii) motion practice, (iv) settlement or injunction posture, and (v) generic entry timing requires docket documents and the specific Orange Book/FDA reference product.

What does “Pfizer Inc. v. Changzhou Pharmaceutical Factory” (1:24-cv-00623) allege?

A correct allegation map depends on three elements:

1. the asserted Pfizer patents (numbers and claims)
2. the FDA submission type (ANDA/BLA) and the drug at issue
3. the infringing product description (strength, dosage form, formulation, labeling)

Without the complaint text and the asserted patent list, a litigation summary would be incomplete. Litigation outcomes and infringement theories cannot be stated reliably based only on the case caption and docket number.

What patent theories are typically pleaded in Pfizer v. generic-filers?

For Pfizer-led pharmaceutical IP disputes in the Hatch-Waxman context, the operative theories usually fall into:

• direct infringement by manufacture/sale of the ANDA product
• infringement under 35 USC § 271(e)(2) based on the FDA approval application
• validity defenses (Section 101/102/103/112) tied to the asserted claims and priority dates
• enforceability defenses around inequitable conduct or prosecution history estoppel, where pleaded

Those are generic patterns and do not replace a docket-specific claim-by-claim analysis.

What patents are asserted in 1:24-cv-00623?

A litigation analysis must list:

• each asserted U.S. patent number
• assignee/patentee on the face of the patent
• the asserted independent claims
• the “Orange Book” listing basis (drug substance vs method of use vs formulation)

This information is contained in the complaint and any infringement contentions. It cannot be derived from the docket number alone.

What is the procedural posture of 1:24-cv-00623?

A docket-specific procedural posture should cover:

• complaint filing date
• answer and any Rule 12 motions
• scheduling order, discovery cutoff
• claim construction if applicable
• summary judgment briefing
• trial or settlement conference dates
• whether Pfizer seeks a preliminary injunction (rare for Hatch-Waxman, common for some biosimilar contexts)

A precise status requires the court docket entries and order history tied to 1:24-cv-00623.

Has the case reached settlement, dismissal, or injunction?

Settlement posture affects generic launch risk through:

• license scope (patent-by-patent covenants not to sue)
• “carve-outs” (e.g., labeling, strength, manufacturing site)
• payment terms (if disclosed)
• timing triggers (design-to-launch or launch-at-risk provisions)
• dismissal-without-prejudice vs consent judgment outcomes

A settlement and its terms require docket documents (stipulation, settlement notice, consent order) and any related press release or court filing.

How does this litigation affect generic or biosimilar entry timing?

A correct exclusivity and entry-timing analysis requires:

• the drug product name at issue
• the FDA reference product (listed drug)
• the Orange Book “with respect to” patents and expiration dates
• whether the case is tied to Paragraph IV (and if so, which patents)

Without the asserted patents and FDA submission details, it is not possible to state:

• launch earliest date under patent/Orange Book expirations
• 180-day exclusivity eligibility and forfeiture risk
• risk of design-around or “at-risk” launch

What is the strength of Pfizer’s patent estate in this case?

Patent strength analysis must be claim-specific and map to litigation facts:

• claim construction indicators (Markman briefs, terms disputed)
• invalidity exposure based on prior art asserted (anticipation vs obviousness)
• written description and enablement challenges (112 issues)
• prosecution history estoppel or terminal disclaimer effects (where relevant)

A strength score without the asserted claim chart or docket claim construction record would be speculative.

How to evaluate strength if you have the asserted claims

When the asserted patents are known, the framework is:

• infringement: does the ANDA product read on each limitation of the asserted claims?
• validity: are the asserted claims vulnerable to the specific prior art combinations used by the defendant?
• remedies: what is Pfizer’s requested relief (injunction vs damages vs declaratory judgment)?
• enforceability: do inequitable conduct issues appear in pleadings?

What defenses does Changzhou typically raise in Hatch-Waxman-style disputes?

Generic defendants often raise:

• non-infringement based on formulation or process differences
• invalidity under 35 USC § 102 and § 103 based on publications or patents
• obviousness combining teachings
• indefiniteness under 35 USC § 112(b)
• lack of enablement or best mode issues (if relevant)
• FDA submission-specific arguments (e.g., labeling carve-outs)

But defenses differ by asserted patents and product description. A litigation summary must cite specific defenses pleaded and any briefing outcomes.

How does this case compare with other Pfizer vs. Chinese generic defendants?

Comparison requires:

• similar asserted Pfizer patents
• common defendant companies or affiliates
• consistent claim constructions and invalidity arguments across districts
• any settlement structures and typical takeaways

A meaningful comparative analysis cannot be performed from the caption alone.

Key Case-File Data (minimum dataset needed for an accurate litigation brief)

Category	Required fields	Source needed
Asserted patents	patent numbers, assignees, asserted claims	complaint / infringement contentions
Product	drug name, strength, dosage form, label	complaint exhibits / ANDA details
FDA pathway	ANDA vs BLA, Paragraph IV vs other	FDA notice of certification / pleadings
Procedural timeline	key docket dates, orders on motions	PACER docket
Outcomes	dismissal, settlement, consent judgment, injunction	stipulations and orders
Remedy request	injunction/damages/declaratory relief	prayer for relief

Key Takeaways

• A docket-number-only request cannot support a complete, accurate litigation summary of Pfizer Inc. v. Changzhou Pharmaceutical Factory (1:24-cv-00623).
• A legally and commercially useful summary requires the asserted-patent list, the FDA submission details, and the docket’s motion and order history.
• Without those records, any statement about infringement theories, validity arguments, or entry timing would not meet the standard for patent and litigation decision-making.

FAQs

1. What court orders determine whether Pfizer can obtain an injunction in 1:24-cv-00623?
2. How do claim construction rulings change non-infringement outcomes for generic products in Pfizer Hatch-Waxman cases?
3. What settlement terms typically restrict “design-around” attempts after a dismissal in ANDA litigation?
4. How does 180-day exclusivity eligibility interact with later-filed Paragraph IV challenges by different filers?
5. What invalidity arguments most frequently succeed against formulation patents asserted by Pfizer?

References

1. (No sources provided in the prompt.)